新型降糖药沙格列汀在中国精神分裂症合并2型糖尿病患者中的药动学和药效学研究

发布时间：2018-07-17 17:26

【摘要】：目的研究沙格列汀片在精神分裂症合并2型糖尿病患者中多次给药后的药动药效学。方法 10例精神分裂症合并2型糖尿病男性住院患者口服沙格列汀片5 mq qd 7 d,在第7天采集12 h内动态血标本,采用HPLC-MS/MS测定血浆中沙格列汀的浓度,同时测定全血样本中血糖水平,并用DAS3.2.4软件对试验数据进行处理,计算药动学参数。结果多次口服沙格列汀片5 mg qd的主要药动学参数ρmax为(16.27±9.28)μg·L-1,tmax为(1.70±0.48)h,t1/2为(3.33±0.59)h,AUC0-12为(45.19±18.67)μg·h·L-1,AUC0-∞为(49.15±19.71)μg·h·L-1。沙格列汀的血药浓度与血糖水平无特异相关性。结论沙格列汀应用于精神分裂症合并2型糖尿病患者药动学特征在正常范围内,安全性较好,对于部分血糖波动较大的患者控制血糖能力一般。
[Abstract]:Objective to study the pharmacodynamics of salgletine tablets in patients with schizophrenia and type 2 diabetes mellitus. Methods 10 inpatients with schizophrenia and type 2 diabetes mellitus were treated with oral salgletine tablets for 7 days. Blood samples were collected within 12 hours on the 7th day. The plasma concentration of salgletine was determined by HPLC-MS / MS. At the same time, the blood glucose level in the whole blood samples was measured, and the experimental data were processed with DAS3.2.4 software, and the pharmacokinetic parameters were calculated. Results the main pharmacokinetic parameter 蟻 max was (16.27 卤9.28) 渭 g / L ~ (-1) t _ (max) = (1.70 卤0.48) h ~ (-1) t ~ (-1) = (3.33 卤0.59) h ~ (-1) AUC0-12 = (45.19 卤18.67) 渭 g / h ~ (-1) AUC0- 鈭，

本文编号：2130399